Change Agents (CHGA) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
25 Aug, 2026Company overview and business model
Operates two segments: AI-driven software (video generation, search optimization) and consumer health (Keto Air breathalyzer).
Recent expansion into AI-powered drone surveillance via new subsidiary Autonomous Air Defense Systems LLC.
AI segment includes Avalon Quantum AI, acquired via RPM Interactive, focusing on agentic video and search tools for small businesses and creators.
Keto Air device is a non-invasive breathalyzer for ketosis monitoring, with exclusive North American distribution rights.
Strategic focus on bolt-on AI acquisitions to supplement revenue as core products develop.
Financial performance and metrics
Net loss from continuing operations was $6.56M for the six months ended June 30, 2026, down 57.8% from prior year.
Working capital deficit decreased to $4.09M at June 30, 2026, from $12.65M at December 31, 2025.
Cash balance was $39K at June 30, 2026; company projects insufficient cash for 12 months of operations.
Accumulated deficit reached $112.6M as of June 30, 2026.
Revenue generation remains limited; meaningful revenue from AI platform expected in about one year.
Use of proceeds and capital allocation
May receive up to $10M in gross proceeds from ELOC Purchase Agreement with Hudson Global Ventures at $0.20/share.
Proceeds intended for debt repayment, working capital, and general corporate purposes; management retains broad discretion.
Required to allocate portions of proceeds to repay specific outstanding promissory notes.
Latest events from Change Agents
- Shareholders will vote on key equity issuances, capital increases, and incentive plan amendments.CHGA
Proxy filing - AI and health tech pivot, ongoing losses, ELOC funding, and dilution risks define this IPO filing.CHGA
Registration filing - Early-stage AI and health tech firm seeks $10M via ELOC, faces losses, liquidity risk, and dilution.CHGA
Registration filing - Shareholders to vote on major equity issuances, warrant exercises, and capital structure changes.CHGA
Proxy filing - All proposals, including director elections and a reverse stock split, were approved.CHGA
AGM 2026 - Net loss narrowed sharply, but liquidity and Nasdaq compliance risks remain elevated.CHGA
Q2 2026 - Stockholders will vote on equity issuances, note conversions, and a charter amendment to increase authorized shares.CHGA
Proxy filing - AI and health tech firm registers 35.6M shares for resale amid ongoing losses and capital needs.CHGA
Registration filing - Net loss from continuing operations surged to $17.5M in 2025 amid a strategic pivot to AI and health tech.CHGA
Q4 2025